Heinz Ludwig

Summary

Country: Austria

Publications

  1. ncbi request reprint Supportive therapies in the management of myeloma
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Oncology (Williston Park) 18:295-6, 298. 2004
  2. ncbi request reprint Anemia in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Vienna, Austria
    Clin Adv Hematol Oncol 2:233-41. 2004
  3. pmc Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
    Roman Hajek
    University Hospital Brno, Czech Republic
    BMC Cancer 12:415. 2012
  4. pmc Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia
    H Ludwig
    Department of Medicine I, Center for Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna, Austria
    Ann Oncol 24:1886-92. 2013
  5. pmc Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
    H Ludwig
    Wilhelminenhospital Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Leukemia 27:213-9. 2013
  6. doi request reprint Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
    Heinz Ludwig
    Wilhelminenspital, Vienna, Austria
    J Clin Oncol 31:247-55. 2013
  7. doi request reprint Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Heinz Ludwig
    1st Department of Medicine, Center for Oncology and Haematology, Vienna, Austria
    Leuk Res 36:S27-34. 2012
  8. pmc European perspective on multiple myeloma treatment strategies: update following recent congresses
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Oncologist 17:592-606. 2012
  9. pmc IMWG consensus on maintenance therapy in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Blood 119:3003-15. 2012
  10. pmc Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009

Detail Information

Publications68

  1. ncbi request reprint Supportive therapies in the management of myeloma
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Oncology (Williston Park) 18:295-6, 298. 2004
  2. ncbi request reprint Anemia in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Vienna, Austria
    Clin Adv Hematol Oncol 2:233-41. 2004
    ..Recently, an international expert panel recommended the use of rHuEPO for anemic myeloma patients where other possible causes of anemia have been eliminated...
  3. pmc Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
    Roman Hajek
    University Hospital Brno, Czech Republic
    BMC Cancer 12:415. 2012
    ....
  4. pmc Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia
    H Ludwig
    Department of Medicine I, Center for Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna, Austria
    Ann Oncol 24:1886-92. 2013
    ..ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue...
  5. pmc Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
    H Ludwig
    Wilhelminenhospital Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Leukemia 27:213-9. 2013
    ..5 months vs median not reached, P=0.016). Multivariate analysis revealed HLC ratio (P=0.03) and β(2)-microglobulin (P<0.01) as independent risk factors for survival...
  6. doi request reprint Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
    Heinz Ludwig
    Wilhelminenspital, Vienna, Austria
    J Clin Oncol 31:247-55. 2013
    ..This phase II, noncomparative study sought to determine whether addition of cyclophosphamide to this regimen (VTDC) could further increase efficacy without compromising safety...
  7. doi request reprint Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Heinz Ludwig
    1st Department of Medicine, Center for Oncology and Haematology, Vienna, Austria
    Leuk Res 36:S27-34. 2012
    ..This article reviews the currently available data on treatments, including novel agents for patients with RRMM, focusing on the duration of therapy required to improve clinical outcomes...
  8. pmc European perspective on multiple myeloma treatment strategies: update following recent congresses
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Oncologist 17:592-606. 2012
    ....
  9. pmc IMWG consensus on maintenance therapy in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Blood 119:3003-15. 2012
    ..Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established...
  10. pmc Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
    ..In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level < or = 10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care...
  11. ncbi request reprint Epoetin beta in oncology: examining the current evidence
    Heinz Ludwig
    Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr 37, A 1171 Vienna, Austria
    Future Oncol 2:21-38. 2006
    ..The approved 30,000 IU once-weekly dosing regimen (as opposed to the 10,000 IU three-times weekly regimen) provides greater convenience and may result in improved treatment compliance...
  12. doi request reprint Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, 1160 Vienna, Austria
    Nat Rev Clin Oncol 7:289-94. 2010
    ..A 51-year-old man presented with an 8 month history of migratory pain and weakness...
  13. pmc Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
    Heinz Ludwig
    Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Haematologica 95:1548-54. 2010
    ..This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma...
  14. doi request reprint Survival and years of life lost in different age cohorts of patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    J Clin Oncol 28:1599-605. 2010
    ..To assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma...
  15. ncbi request reprint Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr 37, 1170 Vienna, Austria
    Haematologica 92:1411-4. 2007
    ..Improvement of renal function was preceded by a significant reduction in paraprotein concentration in all patients, with improvement in renal function...
  16. pmc Current multiple myeloma treatment strategies with novel agents: a European perspective
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Oncologist 15:6-25. 2010
    ..This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents...
  17. ncbi request reprint Supportive care in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstrasse 37, 1170 Vienna, Austria
    Best Pract Res Clin Haematol 20:817-35. 2007
    ..In progressive disease, certain measures such as adequate pain control and radiotherapy can ameliorate symptoms until the therapeutic effect of systemic anti-neoplastic therapy becomes evident...
  18. doi request reprint Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia
    Heinz Ludwig
    Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Pavillion 23, Montleartstrasse 37, Vienna 1160, Austria
    J Clin Oncol 27:2838-47. 2009
    ....
  19. doi request reprint Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria
    Blood 113:3435-42. 2009
    ..5 vs 49.4 months; P= .024). Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status. The study was registered at ClinicalTrials.gov as NCT00205751...
  20. doi request reprint Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  21. doi request reprint Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    J Clin Oncol 28:4635-41. 2010
    ..To assess the efficacy of bortezomib-doxorubicin-dexamethasone (BDD) therapy in patients with multiple myeloma with light chain-induced acute renal failure...
  22. doi request reprint Supportive therapy in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Montleartstr 37, 1160, Vienna, Austria
    Recent Results Cancer Res 183:307-33. 2011
    ....
  23. ncbi request reprint Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies
    Heinz Ludwig
    First Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Cancer 104:1794-807. 2005
    ..Further studies with bortezomib as monotherapy and in combination regimens in the treatment of solid and hematologic malignancies are warranted...
  24. ncbi request reprint The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
    Heinz Ludwig
    Department of Medical Oncology, Wilhelminenspital, Vienna, Austria
    Eur J Cancer 40:2293-306. 2004
    ..5%). Mean haemoglobin to initiate anaemia treatment was 9.7 g/dL. Anaemia prevalence and incidence in cancer patients are high. Anaemia significantly correlates with poor performance status and many anaemic patients are not treated...
  25. pmc Multiple myeloma treatment strategies with novel agents in 2011: a European perspective
    Heinz Ludwig
    Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Oncologist 16:388-403. 2011
    ..This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices...
  26. ncbi request reprint Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Br J Haematol 131:329-37. 2005
    ..In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome...
  27. ncbi request reprint Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia
    Kathrin Strasser-Weippl
    First Medical Department, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
    Cancer 107:2801-6. 2006
    ..Interphase fluorescent in situ hybridization (FISH) can partly overcome these limitations and increase the sensitivity of cytogenetic assessment in MF...
  28. doi request reprint High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Daniel Heintel
    Department of Internal Medicine I, Center for Oncology and Haematology, Wilhelminenspital, Vienna, Austria
    Br J Haematol 161:695-700. 2013
    ..CRBN expression is closely associated with IRF4, which is an important target of IMiD therapy...
  29. ncbi request reprint Epoetin alfa: future directions and future research
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Oncologist 9:70-3. 2004
  30. doi request reprint Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study
    Heinz Ludwig
    Medizinische Abteilung I Onkologie und Haematologie, Wilhelminenspital, Montleartstrasse 37, Wien 1160, Austria
    Eur J Cancer 45:1603-15. 2009
    ..To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe...
  31. ncbi request reprint rHuEPO and treatment outcomes: the preclinical experience
    Heinz Ludwig
    Department of Medicine and Medical Oncology, 1st Medical Department Oncology, Wilhelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Oncologist 9:48-54. 2004
    ..Overall, these preclinical findings suggest that correction of anemia by rHuEPO can increase tumor sensitivity to both radiation therapy and chemotherapy and that epoetin alfa may exert an immunomodulatory effect in multiple myeloma...
  32. ncbi request reprint Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score
    Kathrin Strasser-Weippl
    First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria
    Leuk Lymphoma 47:441-50. 2006
    ..This is in contrast to previous prognostic scores, in which the poor prognosis group was often very small and/or could not be consistently differentiated from patients with an intermediate prognosis...
  33. doi request reprint Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma
    Kathrin Strasser-Weippl
    1st Medical Department, Center for Haematology and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Eur J Haematol 81:374-9. 2008
    ..Taken together, QOL was found to be significantly impaired in myeloma patients at start of therapy. Psychosocial, but not physical dimensions of QOL were found to be independent prognostic factors...
  34. ncbi request reprint Supportive treatment for anemic cancer patients
    Gudrun M I Pohl
    Ist Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Wien Med Wochenschr 154:226-34. 2004
    ..Supportive treatment of anemic cancer patients presenting anemia-related symptoms should be performed to reduce symptoms in cancer patients and optimize outcome to anticancer therapy...
  35. doi request reprint Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan
    Niklas Zojer
    First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Eur J Haematol 81:322-4. 2008
    ..To our knowledge, this is the first report on the use of an anti-CD20 radiolabeled antibody for the treatment of LPHL...
  36. ncbi request reprint Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wihelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Hematol J 3:121-30. 2002
    ..Epoetin treatment should be discontinued if there is no response to the increased dosage, or hemoglobin >14 g/dl. Treatment should resume for patients who exceed 14 g/dl, at a reduced dosage, if their hemoglobin falls below 12 g/dl...
  37. ncbi request reprint Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma
    Niklas Zojer
    First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Austria
    Leuk Lymphoma 47:1103-9. 2006
    ..Taken together, rituximab treatment yielded significant reductions in circulating B cells and serum IgM levels but had no beneficial clinical effect...
  38. ncbi request reprint Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance
    Niklas Zojer
    First Department of Internal Medicine and Medical Oncology, Wilhelminenspital, University of Vienna, Montleartstrasse 37, 1160 Vienna, Austria
    Br J Haematol 117:852-9. 2002
    ..These results provide evidence that the circulating clonotypic B cells are closely related to the malignant plasma cells in myeloma and MGUS...
  39. doi request reprint Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
    Johanna Atamaniuk
    Department of Medicine I, Division of Hematology and Hemostaseology, Medical University Vienna, Austria
    Eur J Clin Invest 42:953-60. 2012
    ..G protein-coupled receptor 5D (GPRC5D) is a novel surface receptor. As this new subtype of G protein-coupled receptors was discovered, little is known about the role of this gene...
  40. ncbi request reprint Thalidomide treatment in multiple myeloma
    Kathrin Strasser
    1st Department of Medicine and Oncology, Wilhelminenspital, Vienna, Austria
    Blood Rev 16:207-15. 2002
    ..In this paper, we will review the available clinical data regarding efficacy and toxicity of thalidomide, discuss its possible mechanism of action and point to future directions of research and clinical development of the ImiDs...
  41. ncbi request reprint A survey among oncologists on measures needed to improve cancer care
    Kathrin Strasser-Weippl
    First Medical Department, Center for Hematology and Oncology, Wilhelminen Hospital, Vienna, Austria
    Onkologie 30:367-72. 2007
    ..There is a continuous need for optimizing cancer care in Europe and globally. We aimed to apprehend the perception of (mainly medical) oncologists with regards to the importance of measures intended to improve the standard of cancer care...
  42. ncbi request reprint "Laying on of hands" improves well-being in patients with advanced cancer
    Gudrun Pohl
    Department of Internal Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr 37, 1171, Vienna, Austria
    Support Care Cancer 15:143-51. 2007
    ....
  43. ncbi request reprint [Anemias]
    Niklas Zojer
    Zentrum für Onkologie und Hämatologie Wilhelminenspital der Stadt Wien, Wien, Osterreich
    Wien Klin Wochenschr 118:69-83; quiz 84. 2006
  44. doi request reprint Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Vienna, Austria
    Blood 123:985-91. 2014
    ..Bendamustine-bortezomib-dexamethasone is active and well tolerated in patients with relapsed/refractory myeloma. This trial was registered in the EudraCT database as No. 2008-006421-13. ..
  45. ncbi request reprint Optimum cancer care--an unaffordable goal?
    Heinz Ludwig
    Department of Medicine and Oncology, Wilhelminenspital, Vienna, Austria
    Lancet Oncol 5:529-30. 2004
  46. doi request reprint Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth
    Sabine Pfeifer
    First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria
    J Cancer Res Clin Oncol 138:1821-30. 2012
    ..By focusing on multiple myeloma cells and its microenvironment as potential sources of IDO, we aimed to delineate its influence on myeloma cell growth and survival and examine effector mechanisms...
  47. doi request reprint Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors
    Siroos Mirzaei
    Institute of Nuclear Medicine with PET Center, Wilhelminenspital, Montleartstrasse 37, Vienna, Austria
    Oncology 80:326-9. 2011
    ..The aim of this study was to compare the lesion detection rate of (99m)Tc-EDDA/HYNIC-TOC, a newly developed tracer for NET imaging, with (177)Lu-DOTATATE used for PRRT...
  48. pmc Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
    Martina Lehnert
    1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
    Onco Targets Ther 2:199-208. 2009
    ..Possible strategies of incorporating ibritumomab tiuxetan into the treatment algorithm of FL are discussed...
  49. pmc Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY
    Gunnar Birgegard
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Eur J Haematol 77:378-86. 2006
    ..Here we define anemia prevalence, incidence, and treatment patterns, and identify anemia risk factors in European L/MM patients...
  50. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  51. ncbi request reprint The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines
    Matti Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Support Care Cancer 16:193-200. 2008
    ..To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described...
  52. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  53. ncbi request reprint Management of multiple myeloma with bortezomib: experts review the data and debate the issues
    Mario Dicato
    Department of Hematology Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
    Oncology 70:474-82. 2006
    ....
  54. ncbi request reprint Cancer-related anemia: pathogenesis, prevalence and treatment
    Gunnar Birgegard
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Oncology 68:3-11. 2005
    ..These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome...
  55. ncbi request reprint Cancer-related anemia: biological findings, clinical implications and impact on quality of life
    Jens Uwe Blohmer
    Sankt Gertrauden Krankenhaus, Berlin Wilmersdorf, Germany
    Oncology 68:12-21. 2005
    ..Systematic correction of anemia with appropriate supportive therapies prior to or during chemotherapy or radiotherapy may enhance patients' QOL...
  56. ncbi request reprint Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    Pere Gascon
    Hospital Clinic, ARIBAU 161, Pral 1a, Barcelona 08036, Spain
    Eur J Cancer 41:2789-91. 2005
  57. ncbi request reprint The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy
    Mark Vincent
    London Regional Cancer Program, 790 Commissioners Road E, London, ON, N6A 4L6, Canada
    Support Care Cancer 15:265-72. 2007
    ..e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described...
  58. ncbi request reprint A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
    ..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment...
  59. ncbi request reprint Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey
    Peter J Barrett-Lee
    Velindre NHS Trust, Cardiff, UK
    Oncology 70:34-48. 2006
    ..To develop a hitherto unavailable risk factor model for accurately predicting anemia development in cancer patients before chemotherapy (CT) administration...
  60. ncbi request reprint Anemia of hematologic malignancies: what are the treatment options?
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelmin Hospital, University of Vienna, Austria
    Semin Oncol 29:45-54. 2002
    ..Representative studies on the efficacy of epoetin alfa in anemic patients with hematologic malignancies as well as models to predict response to epoetin alfa treatment are summarized...
  61. doi request reprint Thalidomide for treatment of multiple myeloma: 10 years later
    Antonio Palumbo
    Division of Hematology, University of Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 111:3968-77. 2008
    ..Future studies will define the most effective or the best sequence of combinations which could improve life expectancy...
  62. ncbi request reprint Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma
    Niklas Zojer
    Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
    Blood 101:4137-9. 2003
    ..Transformation can occur at either MGUS stage, but it involves a single cell in which somatic mutation is then silent...
  63. ncbi request reprint ESMO committed to improving cancer education
    Heinz Ludwig
    European Society for Medical Oncology, Via la Santa 7, 6962, Viganello Lugano, Switzerland
    Lancet Oncol 4:71-2. 2003
  64. ncbi request reprint [Rethinking in oncology. More quality of life for patients by information? (interview by Christine Vetter)]
    Heinz Ludwig
    MMW Fortschr Med 144:16. 2002
  65. doi request reprint Erythropoietins should be used according to guidelines
    Matti S Aapro
    Lancet Oncol 9:412-3. 2008
  66. doi request reprint The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008
  67. ncbi request reprint Keynote comment: inequalities and shortcomings in European cancer care
    Heinz Ludwig
    Lancet Oncol 7:276-7. 2006
  68. doi request reprint Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Robert E Smith
    South Carolina Oncology Associates, Columbia, SC, USA
    J Clin Oncol 26:1040-50. 2008
    ..The efficacy and safety of darbepoetin alpha (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated...